Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib in children aged 4 to 11 years with APDS
NL-OMON53548Phase 3Recruiting
- Sponsor
- Pharming Group
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leniolisib in Activated PI3Kδ syndrome (APDS), sponsored by Pharming Group. Primary endpoints: Incidence of treatment-emergent adverse events, Change in clinical laboratory test results and 6 more. Started Oct 2023; status: recruiting.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on NL-OMON53548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53548.